Last Updated : April 14, 2025
Details
FilesGeneric Name:
dupilumab
Project Status:
Active
Therapeutic Area:
Prurigo nodularis (PN)
Manufacturer:
sanofi-aventis Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0876-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with moderate-to-severe PN whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Dupixent is indicated for the treatment of adult patients with moderate-to-severe prurigo nodularis (PN) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | November 12, 2024 |
|---|---|
| Call for patient/clinician input closed | January 10, 2025 |
| Submission received | December 20, 2024 |
| Submission accepted | January 13, 2025 |
| Review initiated | January 14, 2025 |
| Draft CADTH review report(s) provided to sponsor for comment | April 09, 2025 |
| Deadline for sponsors comments | April 22, 2025 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | May 15, 2025 |
| Expert committee meeting (initial) | May 28, 2025 |
| Draft recommendation issued to sponsor | June 09, 2025 To June 11, 2025 |
| Draft recommendation posted for stakeholder feedback | June 19, 2025 |
| End of feedback period | July 04, 2025 |
Files
Last Updated : April 14, 2025